Fold: no special thoughts on the trial. Maybe interest due to ert shortages.
I actually like the idea of chaperone+ERT just more for Pompe where need to get better uptake in some cells. I haven't looked at interim data in much detail to speculate on how good it is. Saw very small patient numbers. Genisi is better person to analyze that too.
For Fabry I thought best opportunity for late onset less symptomatic patients who may not want hassle of ERT but this will take a lot of effort to reach/penetrate.
FOLD is up another ~10% today that is quite the move the past few days! It may just settle at that $6 you mentioned, congrats if you own it! I heard the presentation again and can't find anything especially noteworthy. It could be just someone trying to buy a descent position but I am wondering what Crowley said in the breakout at JPM :-).
News 
Market Data 
Discover 
